| Inclusion Criteria: | 1) Subject has completed participation in a GSK-sponsored study of pazopanib and remains eligible for continued treatment with pazopanib. Subjects will be stratified into: Group 2 - monotherapy study of pazopanib; or Group 3 - combination of pazopanib and lapatinib with or without another approved marketed agent(s). i. Remains eligible for continued treatment with lapatinib. ii. Has a left ventricular ejection fraction (LVEF) >/=50% based on ECHO or MUGA or within the institutional normal range;
2) ( 1. continued) or Group 4 - combination of pazopanib and an approved marketed agent(s), other than lapatinib. i. Remains eligible for continued treatment with approved marketed agent(s), other than lapatinib.
3) Women subject: 1) Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is: a) pre-menopausal with a documented bilateral oophorectomy (ovariectomy), bilateral tubal ligation or hysterectomy b) post-menopausal defined as a total cessation of menses for >/=1 year (in questionable cases, a blood sample with simultaneous follicle stimulating hormone [FSH] >40 MlU/mL and estradiol <40 pg/mL <140 pmol/L] is confirmatory).
4) ( 3. continued) 2) Child-bearing potential who has a negative serum pregnancy testing at time of transition to this study, and agrees to use 1 of the contraception methods for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point.
5) Subject is a man with a female partner of childbearing potential agrees to use contraception with acceptable methods.
6) Subject, if sexually active, agrees to continue the recommended contraceptive measures for the duration of treatment and for 28 days following discontinuation of treatment.
7) Subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
|